bortezomib
Showing 26 - 50 of 559
Multiple Myeloma Based on Multi-omics
Enrolling by invitation
- Multiple Myeloma
- Bortezomib
- Bortezomib
-
Beijing, ChinaBeijng Chao Yang Hospital
Apr 21, 2022
Multiple Myeloma, Refractory Multiple Myeloma Trial (procedure, drug, radiation)
Withdrawn
- Multiple Myeloma
- Refractory Multiple Myeloma
- nonmyeloablative allogeneic hematopoietic stem cell transplantation
- +7 more
- (no location specified)
Jan 4, 2023
GVHD Trial in New York (Bortezomib, Cyclophosphamide)
Active, not recruiting
- GVHD
- Bortezomib
- Cyclophosphamide
-
New York, New YorkNew York University School of Medicine
Apr 15, 2022
Primary Systemic Amyloidosis, Light Chain Deposition Disease Trial in United States (drug, genetic, other, procedure)
Active, not recruiting
- Primary Systemic Amyloidosis
- Light Chain Deposition Disease
- bortezomib
- +6 more
-
Denver, Colorado
- +6 more
Aug 24, 2022
Graft-versus-host Disease Trial in New York (Cyclophosphamide, Abatacept, Bortezomib)
Recruiting
- Graft-versus-host Disease
- Cyclophosphamide
- +2 more
-
New York, New YorkNYU Langone Health
Mar 24, 2022
Hematological Malignancy Trial in Detroit (Bortezomib)
Recruiting
- Hematological Malignancy
- Bortezomib
-
Detroit, MichiganHenry Ford hospital
Dec 23, 2021
Multiple Myeloma Trial in Chicago, Milwaukee (Bortezomib, Isatuximab, Cyclophosphamide)
Recruiting
- Multiple Myeloma
- Bortezomib
- +3 more
-
Chicago, Illinois
- +1 more
Mar 14, 2022
Lymphoma, Mantle Cell, Mantle Cell Lymphoma Trial run by the NCI (Rituximab (R), EPOCH, Bortezomib (B))
Active, not recruiting
- Lymphoma, Mantle Cell
- Mantle Cell Lymphoma
- Rituximab (R)
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 21, 2021
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (drug, other, biological)
Active, not recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +4 more
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Aug 5, 2022
Lymphoma, Relapsed/Refractory T-cell Lymphomas Trial in United States (Romidepsin, Bortezomib, duvelisib)
Active, not recruiting
- Lymphoma
- Relapsed/Refractory T-cell Lymphomas
- Romidepsin
- +2 more
-
Stanford, California
- +10 more
Feb 2, 2023
Plasma Cell Myeloma Trial in Worldwide (lenalidomide, bortezomib, cyclophosphamide)
Active, not recruiting
- Plasma Cell Myeloma
- lenalidomide
- +4 more
-
Nantes Cedex 01, France
- +11 more
May 3, 2022
Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease Trial in Mexico City (Bortezomib)
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +2 more
- Bortezomib
-
Mexico City, MexicoHospital General de México "Dr. Eduardo Liceaga"
Jan 2, 2022
Multiple Myeloma Trial in Washington, Hackensack (Melphalan, Bortezomib)
Active, not recruiting
- Multiple Myeloma
- Melphalan
- Bortezomib
-
Washington, District of Columbia
- +1 more
May 6, 2022
Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin Trial in Ann Arbor (Bortezomib, Ruxolitinib)
Completed
- Hodgkin's Lymphoma
- Lymphoma, Non-Hodgkin
- Bortezomib
- Ruxolitinib
-
Ann Arbor, MichiganUniversity of Michgan Comprehensive Cancer Center
Dec 3, 2021
Multiple Myeloma Trial in Germany (Teclistamab (Tec), Daratumumab, Dexamethasone)
Recruiting
- Multiple Myeloma
- Teclistamab (Tec)
- +4 more
-
Berlin, Germany
- +8 more
Jan 19, 2023
Maintenance With Bortezomib Plus Daratumumab After Induction
Recruiting
- Multiple Myeloma
- Non-eligible for Autologous Stem Cell Transplantation (ASCT)
- Bortezomib
- Daratumumab
-
Arganda Del Rey, Spain
- +31 more
Sep 15, 2022
Newly Diagnosed Multiple Myeloma Trial in Germany (Isatuximab, Lenalidomide, Bortezomib)
Not yet recruiting
- Newly Diagnosed Multiple Myeloma
- Isatuximab
- +4 more
-
Hamburg, Germany
- +3 more
Dec 16, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (Bortezomib, Dexamethasone, Pelareorep)
Not yet recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Bortezomib
- +3 more
-
Los Angeles, California
- +1 more
Aug 19, 2022
Multiple Myeloma Trial in Atlanta (Bortezomib, Lenalidomide, Dexamethasone)
Completed
- Multiple Myeloma
- Bortezomib
- +3 more
-
Atlanta, GeorgiaEmory University Winship Cancer Institute
Nov 1, 2021
Multiple Myeloma Trial in United States (Bortezomib, Lenalidomide, Dexamethasone)
Active, not recruiting
- Multiple Myeloma
- Bortezomib
- +2 more
-
Denver, Colorado
- +7 more
Feb 11, 2022